FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Evolving targets for heart failure: the journey so far
2372pdf: 440HTML: 4
1 - 2 of 2 items
authors
indexing
INDEXING
iCARDIO
May 1 marked the release of the #iCARDIO Guidelines on Heart Failure, now live in Global Cardiology. This global-first effort brings flexible, practical guidance to frontline providers managing #heartfailure in any setting. www.globalcardiology.info/site/article... #GlobalHealth #cardiosky
— iCardio (@icardio.bsky.social) May 13, 2025 at 8:26
[image or embed]
Keywords
Vol. 4 No. 1 (2026)
Ischemic heart disease (IHD) remains the leading cause of morbidity and mortality worldwide. Coronary artery disease (CAD) encompasses any pathological process capable of compromising myocardial perfusion and although numerous etiologies exist, including vasculitis, spontaneous coronary artery dissection, and coronary embolism, the majority of CAD is attributable to coronary atherosclerosis, which constitutes the focus of this document. For practical purposes, CAD is considered present when any degree of atherosclerotic involvement...
Writing Task Force | iCARDIO-Alliance
5 February 2026
Vol. 4 No. 2 (2026)
The Digoxin in Rheumatic Heart Disease (Dig-RHD) trial marks an important shift in rheumatic heart disease by replacing long-standing therapeutic assumption with direct randomized evidence. In a condition affecting predominantly young patients in low- and middle- income countries, practice has often relied on extrapolation from non-valvular heart failure populations despite clear differences in disease biology, treatment access, and clinical context. By reducing heart failure events in symptomatic patients, Dig-RHD suggests that the value...
Viana Copeland et al.
3 July 2026
Vol. 4 No. 2 (2026)
Familial hypercholesterolemia (FH) affects about 20 million people worldwide and remains markedly underdiagnosed and undertreated. Contemporary studies estimate the prevalence of heterozygous FH (HeFH) at 1 in 192 to 1 in 310, and the prevalence of homozygous FH (HoFH) at about 1 in 300,000. The 2016 United States National Health and Nutrition Examination Survey estimated FH prevalence at 1 in 250 adults. Untreated HeFH causes fatal coronary events before age 55 in about 50% of men and before age 60 in about 15% of women. Pathogenic...
Ahmed Kamal Siddiqi et al.
29 June 2026
